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First-in-human clinical trial for age-related macular degen-
eration using iPSC-derived retinal pigment epithelium (RPE)
cells was conducted in 2014, showing no serious adverse
effects to date, including tumor formation. This appears to be
attributable to relatively small number of transplanted cells,
and distinct morphology of RPE cells; it might be relatively
easy to minimize contamination of undifferentiated cells.
However, in the case of clinical trial using iPSC-derived
cardiomyocytes, 108–109 cells would be required for trans-
plantation; strict control of residual undifferentiated cells
should be necessary for safer clinical application.
Accumulating evidence demonstrates several interesting
methods of depleting undifferentiated cells, as shown pre-
viously (Masuda et al., 2014). We can classify these meth-
ods as positive selection or negative selection; in positive
selection, differentiated cells that are positive for differen-
tiation markers would be collected, whereas in negative
selection, undifferentiated cells would be discarded, thus
enabling to eliminate tumorigenic cells from iPSC-derived
products. For negative selection, in most cases, molecular-
targeted drugs have been used to kill iPSCs, such as small
chemicals or antibodies (especially those conjugated with
cytotoxic drugs). Very recently, three papers (Tateno et al.,
2015; Huskey et al., 2015; Wu et al., 2015) have been
published, demonstrating that novel different methods might
be useful for removing tumorigenic iPSCs (Table 1) (Fig. 1).
Previously, Tateno and colleagues discovered that a
lectin, called rBC2LCN, binds to human iPSCs and embry-
onic stem cells (ESCs), but not to differentiated cells (Tateno
et al. 2011). Lectin is known to be protein that binds to glycan
structure. Recently, they newly generated a recombinant
lectin-toxin fusion protein (rBC2LCN-PE23) (Tateno et al.
2015); a catalytic domain of Pseudomonas aeruginosa
exotoxin A was fused with rBC2LCN to eliminate human
iPSCs. Notably, lectin-toxin fusion protein (rBC2LCN-PE23)
could bind to and successfully be internalized by human
iPSCs, suggesting that lectin (rBC2LCN) could be useful for
delivery of cytotoxic agents into human iPSCs. Furthermore,
within 24 h, complete elimination of human iPSCs was
achieved by culture in the presence of lectin-toxin fusion
protein, indicating that rBC2LCN-PE23 exerts a robust cy-
totoxic effect on human iPSCs. On the other hand, it has a
negligible cytotoxic effect on differentiated cells, thereby
enabling selective elimination of human iPSCs in a mixed
cell population (Tateno et al. 2015).
In the present study by Tateno and colleagues, although
selective elimination of human iPSCs was examined in a
mixed cell population (where human ﬁbroblasts were spiked
by human iPSCs) (Tateno et al. 2015), differentiated cells
(derived from human iPSCs) containing undifferentiated cells
should be examined precisely in the future. For example,
even among partially differentiated cells that lost lectin-
binding (i.e. “lectin-negative” cells), there may be a risk of
residual tumorigenic potential. Another issue to be ad-
dressed is that “bystander effect” of lectin-toxin fusion protein
should be investigated; it would be checked whether cleaved
toxin released from dying cells might affect surrounding cell’s
viability. If we are able to replace exotoxin A with other toxins
(proteins) for fusion, it would be interesting. Next issue is
that, from the view point of 3D culture, it would be rather
difﬁcult for lectin-toxin fusion protein to be internalized into
3D tissues.
Second, Huskey and colleagues have identiﬁed that cy-
clin-dependent kinase (CDK) 1 (and its binding partners:
cyclins A2 and B1/B2) would be critical for cell proliferation
and survival in mouse and human ESCs by screening of
siRNA knockdown (Huskey et al. 2015). The authors
demonstrated that purvalanol A, a CDK1 inhibitor, could
preferentially induce cell death in ESCs while sparing dif-
ferentiated cells. In the present study, the authors used an
alternative CDK inhibitor, dinaciclib, developed by Merck,
with improved pharmacokinetic properties compared to
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purvalanol A. Dinaciclib inhibits CDK1, 2, 5, and 9, and is
currently in clinical trials against multiple tumors. Although
Ibrance® by Pﬁzer (Palbociclib) (a CDK4/6 inhibitor) has
been recently approved by FDA for the ﬁrst time as a CDK
inhibitor, CDK4/6 inhibition is known to be compensated by
CDK1 activity. Anyway, there is unique dependency of ESCs
on CDK1 activity (Huskey et al. 2015).
Third, Wu and colleagues investigated whether BRD4, a
member of BET family, interacts with pluripotency-associat-
ed transcription factors (Wu et al. 2015). BRD4 is known to
form active transcription complex, which consists of CDK9,
CYCLIN T, and BRD4. Therefore, the authors treated mouse
ESCs with ﬂavopiridol, a CDK9 inhibitor, and observed that
Nanog and c-Myc expressions were greatly decreased (Wu
et al. 2015). Further elucidation will be needed to examine
whether CDK9 inhibition is associated with ESC survival.
When we utilize iPSC-derived cells for clinical application,
there are two types of tumor cells; a tumor (i.e. benign ter-
atoma) derived from undifferentiated cells, and a tumor
derived from differentiated cells. The latter may be malignant
tumors, potentially with several mutations. Although we can
prevent teratoma formation (the former part) by using
emerging technology as mentioned above, it would be
essential to pre-examine genome sequence of iPSC-derived
products in order to prevent the occurrence of malignant
tumors (the latter part). In summary, now, we can choose or
combine several ways of preventing teratoma formation,
depending on efﬁcacy and safety/toxicity, via ex vivo purging
of undifferentiated cells.
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Table 1. Novel methods for putative prevention of teratoma formation
Tateno et al. (2015) Huskey et al. (2015) Wu et al. (2015)
Chemical or protein Lectin-toxin fusion protein Chemical Chemical
Mode of action Lectin-binding to iPSCs
Cargo of cytotoxic agent
CDK1 inhibition CDK9 inhibition













Figure 1. Recent advances in selective elimination of
human and/or mouse pluripotent stem cells. (A) A recom-
binant lectin-toxin fusion protein (rBC2LCN-PE23) preferentially
binds to and is internalized by human pluripotent stem cells,
thus killing human pluripotent stem cells selectively (Tateno
et al. 2015). (B) CDK1 inhibitors (Purvalanol A and Dinaciclib)
are potent in inducing apoptosis in human and mouse ESCs.
Treatment with a CDK1 inhibitor is demonstrated to prevent
tetatoma formation (Huskey et al. 2015). (C) A CDK9 inhibitor
(Flavopiridol) is shown to decrease Nanog and c-Myc expres-
sions in mouse ESCs (Wu et al. 2015). It remains to be
determined whether CDK9 inhibition results in prevention of
teratoma formation.
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